PhenoVista Biosciences, a San Diego, California-based provider of imaging-based, phenotypic assay services, secured funding from BroadOak Capital Partners, a life science-focused investor.
The amount of the deal was not disclosed.
The investment will be used to develop new complex products, such as models of the blood-brain barrier and platforms for better understanding neurodegenerative diseases.
Led by James G. Evans, CEO and co-founder, PhenoVista is a provider of customized, imaging-based, phenotypic assay services to biopharmaceutical clients that range from local start-ups to multi-national organizations. Their diverse repertoire includes working with primary cells, iPSC-derived neurons, and client-engineered lines in 2D, 3D, co-culture, and microfluidic systems to construct myriad functional, structural, and pre-clinical, therapeutic assays tackling challenges in all areas of biology, from immunology and fibrosis to neurodegenerative diseases.
The company’s team is comprised of experts in diverse fields, such as imaging, assay development, high-throughput and high-content data analysis, microfluidics, machine learning and AI, and advanced cell culture, including primary cells, neurons, organoids, and spheroids.